The Maharashtra Food and Drug Administration (FDA) has confirmed that the controversial ‘Coldrif’ cough syrup, recently banned in Tamil Nadu following child fatalities, did not enter the Maharashtra market. The clarification, issued on October 5, 2025, comes amid growing public concern over the spread of unsafe pharmaceutical products across state borders. Maha FDA officials stated that after an extensive inspection of wholesalers, distributors, and pharmacies, no consignments of the product were found within the state. The department also directed local drug inspectors to remain alert and monitor for any unauthorized shipments that might attempt to bypass state-level restrictions. The confirmation aims to reassure consumers and prevent panic, particularly among parents concerned about children’s safety. The agency further announced plans to tighten surveillance and improve inter-state coordination with health departments to prevent the circulation of potentially hazardous drugs. Meanwhile, public health experts have called for a nationwide review of pediatric medicines and over-the-counter formulations, emphasizing stricter quality control to ensure that such incidents do not recur. #MaharashtraFDA #ColdrifCoughSyrup #DrugSafety #PublicHealth #ChildSafety #PharmaRegulation #HealthNews #MedicalSafety #QualityControl #IndiaHealth
